Recent News

• 10.19.2026 - Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
• 09.21.2026 - Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
• 09.01.2026 - Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
• 05.12.2026 - Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
• 05.11.2026 - Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
• 05.04.2026 - Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
• 04.24.2026 - Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
• 04.20.2026 - Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
• 03.27.2026 - Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
• 03.27.2026 - Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Recent Filings

• 10.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.01.2026 - 144 Report of proposed sale of securities
• 09.21.2026 - 10-KT Transition reports [Rule 13a-10 or 15d-10]
• 09.21.2026 - 8-K Current report
• 09.21.2026 - EX-99.1 EX-99.1
• 09.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.11.2026 - 8-K Current report
• 08.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2026 - 4 Statement of changes in beneficial ownership of securities